Back

Panel discussion - PCSK9 inhibitors: the next chapter in CVD prevention.

27 August 2017 (13:30 - 13:40)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention Lipids Open Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

4 More presentations in this session

Presentation thumbnail
Introduction - PCSK9 inhibitors: the next chapter in CVD prevention.
Video
Presentation thumbnail
CVD prevention and event reduction.
Professor M. Sabatine (Boston, US)
Presentation thumbnail
Future perspectives in lipid lowering and CVD prevention.
Professor P. Sever (London, GB)
Presentation thumbnail
Close - PCSK9 inhibitors: the next chapter in CVD prevention.
Professor J. Chapman (Paris, FR)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

The Event

Event poster

ESC Congress 2017

27 August 2017 13:30 CET
You may be interested in
thumbnail
Congress Session
PCSK9 inhibitors for acute coronary syndromes: the era of early implementation
30 August 2024
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Webinar
Injectable therapies for cardiovascular disease: optimising their use in practice - experiences from the UK and Italy
18 March 2022
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources